1. Subjects who are participating in any other clinical trial or experimental treatment for COVID-19. <br/ >2. Subjects with persistent vomiting (more than three episodes of vomiting in 12 hours) and who cannot tolerate oral drugs. <br/ >3. Subjects requiring concomitant use of invasive or non-invasive mechanical ventilation. <br/ >4. Subjects requiring vasopressors or ionotropic medications. <br/ >5. Subjects requiring anti-viral drugs like ritonavir, favipirir, lopinavir or monoclonal antibodies like tocilizumab at hospitalization, in the opinion of the Investigator. <br/ >6. Female subjects who are pregnant or lactating. <br/ >7. Subjects who are known to be HIV positive or positive for Hepatitis B or C. (The same may be noted based on history given by the subject or standards of care followed at the individual sites.) <br/ >8. Subjects with history of retinopathy or macular degeneration. <br/ >9. Subjects with prolonged QTc interval at screening ( >450 ms in males and >470 ms in females). <br/ >10. Subjects with liver enzymes (namely alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)) > 5x upper limit of normal. <br/ >11. Subjects with creatinine clearance <50 ml/min (using Cockgroft-Gault formula). <br/ >12. Subjects who are not deemed fit as per the investigator for any other medical reason

1. Subjects who are participating in any other clinical trial or experimental treatment for COVID-19. <br/ >2. Subjects with persistent vomiting (more than three episodes of vomiting in 12 hours) and who cannot tolerate oral drugs. <br/ >3. Subjects requiring concomitant use of invasive or non-invasive mechanical ventilation. <br/ >4. Subjects requiring vasopressors or ionotropic medications. <br/ >5. Subjects requiring anti-viral drugs like ritonavir, favipirir, lopinavir or monoclonal antibodies like tocilizumab at hospitalization, in the opinion of the Investigator. <br/ >6. Female subjects who are pregnant or lactating. <br/ >7. Subjects who are known to be HIV positive or positive for Hepatitis B or C. (The same may be noted based on history given by the subject or standards of care followed at the individual sites.) <br/ >8. Subjects with history of retinopathy or macular degeneration. <br/ >9. Subjects with prolonged QTc interval at screening ( >450 ms in males and >470 ms in females). <br/ >10. Subjects with liver enzymes (namely alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)) > 5x upper limit of normal. <br/ >11. Subjects with creatinine clearance <50 ml/min (using Cockgroft-Gault formula). <br/ >12. Subjects who are not deemed fit as per the investigator for any other medical reason

N/A

N/A

1. Subjects who are participating in any other clinical trial or experimental treatment for COVID-19. <br/ >2. Subjects with persistent vomiting (more than three episodes of vomiting in 12 hours) and who cannot tolerate oral drugs. <br/ >3. Subjects requiring concomitant use of invasive or non-invasive mechanical ventilation. <br/ >4. Subjects requiring vasopressors or ionotropic medications. <br/ >5. Subjects requiring anti-viral drugs like ritonavir, favipirir, lopinavir or monoclonal antibodies like tocilizumab at hospitalization, in the opinion of the Investigator. <br/ >6. Female subjects who are pregnant or lactating. <br/ >7. Subjects who are known to be HIV positive or positive for Hepatitis B or C. (The same may be noted based on history given by the subject or standards of care followed at the individual sites.) <br/ >8. Subjects with history of retinopathy or macular degeneration. <br/ >9. Subjects with prolonged QTc interval at screening ( >450 ms in males and >470 ms in females). <br/ >10. Subjects with liver enzymes (namely alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)) > 5x upper limit of normal. <br/ >11. Subjects with creatinine clearance <50 ml/min (using Cockgroft-Gault formula). <br/ >12. Subjects who are not deemed fit as per the investigator for any other medical reason

1. Subjects who are participating in any other clinical trial or experimental treatment for COVID-19. <br/ >2. Subjects with persistent vomiting (more than three episodes of vomiting in 12 hours) and who cannot tolerate oral drugs. <br/ >3. Subjects requiring concomitant use of invasive or non-invasive mechanical ventilation. <br/ >4. Subjects requiring vasopressors or ionotropic medications. <br/ >5. Subjects requiring anti-viral drugs like ritonavir, favipirir, lopinavir or monoclonal antibodies like tocilizumab at hospitalization, in the opinion of the Investigator. <br/ >6. Female subjects who are pregnant or lactating. <br/ >7. Subjects who are known to be HIV positive or positive for Hepatitis B or C. (The same may be noted based on history given by the subject or standards of care followed at the individual sites.) <br/ >8. Subjects with history of retinopathy or macular degeneration. <br/ >9. Subjects with prolonged QTc interval at screening ( >450 ms in males and >470 ms in females). <br/ >10. Subjects with liver enzymes (namely alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)) > 5x upper limit of normal. <br/ >11. Subjects with creatinine clearance <50 ml/min (using Cockgroft-Gault formula). <br/ >12. Subjects who are not deemed fit as per the investigator for any other medical reason

1. Subjects who are participating in any other clinical trial or experimental treatment for COVID-19. <br/ >2. Subjects with persistent vomiting (more than three episodes of vomiting in 12 hours) and who cannot tolerate oral drugs. <br/ >3. Subjects requiring concomitant use of invasive or non-invasive mechanical ventilation. <br/ >4. Subjects requiring vasopressors or ionotropic medications. <br/ >5. Subjects requiring anti-viral drugs like ritonavir, favipirir, lopinavir, remdesivir or monoclonal antibodies like tocilizumab at hospitalization, in the opinion of the Investigator. <br/ >6. Female subjects who are pregnant or lactating. <br/ >7. Subjects who are known to be HIV positive or positive for Hepatitis B or C. (The same may be noted based on history given by the subject or standards of care followed at the individual sites.) <br/ >8. Subjects with history of retinopathy or macular degeneration. <br/ >9. Subjects with prolonged QTc interval at screening ( >450 ms in males and >470 ms in females). <br/ >10. Subjects with liver enzymes (namely alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)) > 5x upper limit of normal. <br/ >11. Subjects with creatinine clearance <50 ml/min (using Cockgroft-Gault formula). <br/ >12. Subjects who are not deemed fit as per the investigator for any other medical reason

1. Subjects who are participating in any other clinical trial or experimental treatment for COVID-19. <br/ >2. Subjects with persistent vomiting (more than three episodes of vomiting in 12 hours) and who cannot tolerate oral drugs. <br/ >3. Subjects requiring concomitant use of invasive or non-invasive mechanical ventilation. <br/ >4. Subjects requiring vasopressors or ionotropic medications. <br/ >5. Subjects requiring anti-viral drugs like ritonavir, favipirir, lopinavir, remdesivir or monoclonal antibodies like tocilizumab at hospitalization, in the opinion of the Investigator. <br/ >6. Female subjects who are pregnant or lactating. <br/ >7. Subjects who are known to be HIV positive or positive for Hepatitis B or C. (The same may be noted based on history given by the subject or standards of care followed at the individual sites.) <br/ >8. Subjects with history of retinopathy or macular degeneration. <br/ >9. Subjects with prolonged QTc interval at screening ( >450 ms in males and >470 ms in females). <br/ >10. Subjects with liver enzymes (namely alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)) > 5x upper limit of normal. <br/ >11. Subjects with creatinine clearance <50 ml/min (using Cockgroft-Gault formula). <br/ >12. Subjects who are not deemed fit as per the investigator for any other medical reason